

Ranjit Akolekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1084213/publications.pdf>

Version: 2024-02-01

198
papers

13,612
citations

30070

54
h-index

24258

110
g-index

209
all docs

209
docs citations

209
times ranked

9027
citing authors

#	ARTICLE	IF	CITATIONS
1	Fetal fraction of cell free DNA in screening for hypertensive disorders at 11â€“13 weeks. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5363-5368.	1.5	5
2	Kiellandâ€™s rotational forceps delivery: comparison of maternal and neonatal outcomes with pregnancies delivering by non-rotational forceps. Journal of Obstetrics and Gynaecology, 2022, 42, 379-384.	0.9	2
3	Secondâ€ trimester contingent screening for smallâ€forâ€gestationalâ€age neonate. Ultrasound in Obstetrics and Gynecology, 2022, 59, 177-184.	1.7	12
4	<sc>STATIN</sc> trial: predictive performance of competingâ€risks model in screening for preâ€eclampsia at 35â€“37â€weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 69-75.	1.7	15
5	Development and validation of model for prediction of placental dysfunctionâ€related stillbirth from maternal factors, fetal weight and uterine artery Doppler at midâ€gestation. Ultrasound in Obstetrics and Gynecology, 2022, 59, 61-68.	1.7	13
6	Risk of fetal loss after chorionic villus sampling in twin pregnancy derived from propensity score matching analysis. Ultrasound in Obstetrics and Gynecology, 2022, 59, 162-168.	1.7	9
7	Predictive performance for placental dysfunction related stillbirth of the competing risks model for smallâ€forâ€gestationalâ€age fetuses. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1530-1537.	2.3	11
8	Maternal race and preâ€eclampsia: Cohort study and systematic review with metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 2082-2093.	2.3	8
9	Maternal Race and Stillbirth: Cohort Study and Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3452.	2.4	6
10	Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. American Journal of Obstetrics and Gynecology, 2021, 224, 86.e1-86.e19.	1.3	50
11	Perinatal outcome of pregnancies with prenatal diagnosis of vasa previa: systematic review and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 57, 710-719.	1.7	29
12	Evaluation of the RCOG guideline for the prediction of neonates that are small for gestational age and comparison with the competing risks model. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 2110-2115.	2.3	15
13	Cellâ€free <sc>DNA</sc> testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10â€“14â€weeks and metaâ€analysis. Ultrasound in Obstetrics and Gynecology, 2021, 58, 178-189.	1.7	28
14	Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2021, 58, 48-55.	1.7	9
15	Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation, 2021, 144, 670-679.	1.6	61
16	Reference Ranges for Pulsed-Wave Doppler of the Fetal Cardiac Inflow and Outflow Tracts from 13 to 36â€Weeksâ€™ Gestation. Journal of the American Society of Echocardiography, 2021, 34, 1007-1016.e10.	2.8	9
17	Estimated fetal weight at midâ€gestation in prediction of preâ€eclampsia in singleton pregnancies. Ultrasound in Obstetrics and Gynecology, 2021, , .	1.7	0
18	Value of routine ultrasound examination at 35â€“37â€weeks' gestation in diagnosis of nonâ€cephalic presentation. Ultrasound in Obstetrics and Gynecology, 2020, 55, 248-256.	1.7	19

#	ARTICLE	IF	CITATIONS
19	Comparison of different methods of measuring angle of progression in prediction of labor outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 391-400.	1.7	13
20	Value of routine ultrasound examination at 35â€“37 weeks' gestation in diagnosis of fetal abnormalities. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 75-80.	1.7	59
21	Diagnosis of major heart defects by routine firstâ€“trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 637-644.	1.7	55
22	Impact of prospective measurement of outflow tracts inÂprediction of coarctation of the aorta. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 850-856.	1.7	19
23	Diagnosis of fetal defects in twin pregnancies at routine 11â€“13â€“week ultrasound examination. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 474-481.	1.7	24
24	Prevention of stillbirth: impact of twoâ€“stage screening for vasa previa. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 605-612.	1.7	32
25	Kiellandâ€™s rotational forceps delivery: A comparison of maternal and neonatal outcomes with rotational ventouse or second stage caesarean section deliveries. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 254, 175-180.	1.1	5
26	Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 246.e1-246.e10.	1.3	17
27	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 953-954.	1.7	0
28	Maternal and Neonatal Complications of Fetal Macrosomia: Systematic Review and Meta-analysis. <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 148-149.	0.4	0
29	Risk of Miscarriage Following Amniocentesis or Chorionic Villus Sampling: Systematic Review of Literature and Updated Meta-analysis. <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 152-154.	0.4	2
30	Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-156.	0.7	5
31	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 659.	1.3	1
32	Diagnosis of fetal nonâ€“chromosomal abnormalities on routine ultrasound examination at 11â€“13â€“weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 468-476.	1.7	172
33	Twoâ€“stage approach for prediction of smallâ€“forâ€“gestationalâ€“age neonate and adverse perinatal outcome by routine ultrasound examination at 35â€“37â€“weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 484-491.	1.7	27
34	Prediction of adverse perinatal outcome by serum placental growth factor and soluble fmsâ€“like tyrosine kinaseâ€“1 in women undergoing induction of labor. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 604-608.	1.7	3
35	Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated metaâ€“analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 442-451.	1.7	217
36	Prediction of largeâ€“forâ€“gestationalâ€“age neonate by routine thirdâ€“trimester ultrasound. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 326-333.	1.7	39

#	ARTICLE	IF	CITATIONS
37	Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 734-742.	1.7	108
38	Fetal intra-abdominal bowel dilation in prediction of complex gastroschisis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 376-380.	1.7	9
39	Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 79-86.	1.7	28
40	Routine assessment of cerebroplacental ratio at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 65.e1-65.e18.	1.3	50
41	Routine ultrasound at 32 vs 36 weeks' gestation: prediction of small-for-gestational-age neonates. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 761-768.	1.7	39
42	Prediction of small-for-gestational-age neonates at 35-37 weeks' gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 630-637.	1.7	18
43	Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 486.e1-486.e11.	1.3	63
44	First-trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 804-809.	1.7	66
45	Procedure-related risk of miscarriage following chorionic villus sampling and amniocentesis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 452-457.	1.7	35
46	Maternal and neonatal complications of fetal macrosomia: cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 319-325.	1.7	38
47	Maternal and neonatal complications of fetal macrosomia: systematic review and meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 54, 308-318.	1.7	144
48	Social Brain Functional Maturation in Newborn Infants With and Without a Family History of Autism Spectrum Disorder. <i>JAMA Network Open</i> , 2019, 2, e191868.	5.9	25
49	Prediction of small-for-gestational-age neonates at 35-37 weeks' gestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 488-495.	1.7	29
50	Prediction of adverse perinatal outcome by cerebroplacental ratio in women undergoing induction of labor. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 473-480.	1.7	30
51	Impaired placental perfusion and major fetal cardiac defects. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 68-72.	1.7	13
52	Fetal Medicine Foundation reference ranges for umbilical artery and middle cerebral artery pulsatility index and cerebroplacental ratio. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 465-472.	1.7	122
53	Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019, 53, 208-213.	1.7	28
54	Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 743-750.	1.7	219

#	ARTICLE	IF	CITATIONS
55	Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 35-43.	1.7	109
56	ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 738-742.	1.7	54
57	Chronic Hypertension and Adverse Pregnancy Outcome: A Cohort Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 7-8.	0.4	1
58	Fetal Medicine Foundation fetal and neonatal population weight charts. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 44-51.	1.7	197
59	Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 52-59.	1.7	91
60	Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. <i>Fetal Diagnosis and Therapy</i> , 2018, 43, 250-265.	1.4	16
61	Fetal major cardiac defects and placental dysfunction at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 194-198.	1.7	24
62	Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007575.	2.6	17
63	Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 186-195.	1.7	241
64	Risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review of the literature. <i>Minerva Obstetrics and Gynecology</i> , 2018, 70, 215-219.	1.0	27
65	Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 751-755.	1.7	182
66	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 383-387.	1.7	27
67	Impaired placentation in women with chronic hypertension who develop pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 496-500.	1.7	21
68	Chronic hypertension and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 228-235.	1.7	112
69	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 666-667.	1.7	0
70	Association of chronic hypertension with birth of small-for-gestational-age neonate. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 361-366.	1.7	31
71	Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. <i>Obstetric Medicine</i> , 2017, 10, 170-173.	1.1	7
72	ASPRE trial: performance of screening for preterm pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 492-495.	1.7	263

#	ARTICLE	IF	CITATIONS
73	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. American Journal of Obstetrics and Gynecology, 2017, 217, 585.e1-585.e5.	1.3	136
74	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 2017, 377, 613-622.	27.0	1,462
75	Metabolomic determination of pathogenesis of late-onset preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 658-664.	1.5	35
76	Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 194-200.	1.7	21
77	Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF. Ultrasound in Obstetrics and Gynecology, 2017, 49, 201-208.	1.7	19
78	Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2017, 49, 73-77.	1.7	27
79	P14...Significance and associations of aberrant right subclavian artery in the fetal cardiology setting. Heart, 2016, 102, A7.2-A8.	2.9	3
80	Reply. Ultrasound in Obstetrics and Gynecology, 2016, 47, 789-789.	1.7	0
81	Uterine artery pulsatility index at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 308-315.	1.7	24
82	Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. Ultrasound in Obstetrics and Gynecology, 2016, 47, 203-209.	1.7	55
83	Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound in Obstetrics and Gynecology, 2016, 47, 705-711.	1.7	80
84	Endoscopic Placental Laser Coagulation in Dichorionic and Monochorionic Triplet Pregnancies. Fetal Diagnosis and Therapy, 2016, 40, 174-180.	1.4	8
85	Prediction of stillbirth from maternal factors, fetal biometry and uterine artery Doppler at 19-24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 624-630.	1.7	21
86	Prediction of stillbirth from placental growth factor at 11-13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 618-623.	1.7	22
87	Prediction of stillbirth from maternal demographic and pregnancy characteristics. Ultrasound in Obstetrics and Gynecology, 2016, 48, 607-612.	1.7	39
88	Prediction of stillbirth from placental growth factor at 19-24 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 631-635.	1.7	15
89	Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks. Ultrasound in Obstetrics and Gynecology, 2016, 48, 613-617.	1.7	34
90	Clinical implementation of routine screening for fetal trisomies in the UK: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound in Obstetrics and Gynecology, 2016, 47, 45-52.	1.7	108

#	ARTICLE	IF	CITATIONS
91	Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 466.e1-466.e8.	1.3	17
92	Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 194-202.	1.7	57
93	Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 698-704.	1.7	124
94	Re: Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147,987 singleton pregnancies. C. B. Wulff, T. A. Gerds, L. Rode, C. K. Ekelund, O. B. Petersen, A. Tabor and the Danish Fetal Medicine Study Group. <i>Ultrasound Obstet Gynecol</i> 2016; 47: 38-44. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 14-14.	1.7	4
95	Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2016, 374, 434-443.	27.0	308
96	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 103.e1-103.e12.	1.3	365
97	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 253-254.	1.7	0
98	Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 437-445.	1.7	53
99	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 755-757.	1.7	2
100	Metabolomic Analysis for First Trimester Down Syndrome Prediction. <i>Obstetric Anesthesia Digest</i> , 2015, 35, 35-36.	0.1	0
101	Umbilical and fetal middle cerebral artery Doppler at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 409-420.	1.7	61
102	First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History. <i>Fetal Diagnosis and Therapy</i> , 2015, 38, 14-21.	1.4	58
103	Prediction of small-for-gestational-age neonates: screening by fetal biometry at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 551-558.	1.7	60
104	Fetal middle cerebral artery and umbilical artery pulsatility index: effects of maternal characteristics and medical history. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 402-408.	1.7	28
105	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 62.e1-62.e10.	1.3	280
106	Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 707-714.	1.7	25
107	Endoscopic Placental Laser Coagulation in Monochorionic Diamniotic Twins with Type II Selective Fetal Growth Restriction. <i>Fetal Diagnosis and Therapy</i> , 2015, 38, 86-93.	1.4	54
108	Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 249-266.	1.7	547

#	ARTICLE	IF	CITATIONS
109	Umbilical and fetal middle cerebral artery Doppler at 35â€“37 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 82-92.	1.7	85
110	Validation of metabolomic models for prediction of early-onset preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 530.e1-530.e10.	1.3	51
111	Procedureâ€related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and metaâ€analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 16-26.	1.7	548
112	Pregnancy Loss Following Amniocentesis or CVS Samplingâ€Time for a Reassessment of Risk. <i>Journal of Clinical Medicine</i> , 2014, 3, 741-746.	2.4	8
113	Biparietal diameter at 11 to 13â€™weeks' gestation in fetuses with holoprosencephaly. <i>Prenatal Diagnosis</i> , 2014, 34, 134-138.	2.3	5
114	Is high fetal nuchal translucency associated with submicroscopic chromosomal abnormalities on array <scp>CGH</scp>?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 620-624.	1.7	49
115	Association between reduced fetal movements at term and abnormal uterine artery Doppler indices. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 548-552.	1.7	27
116	First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical Testing. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 118-126.	1.4	108
117	Timing of birth in multiple pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2014, 28, 319-326.	2.8	9
118	Prenatal prediction of need for ventriculoperitoneal shunt in open spina bifida. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 159-164.	1.7	20
119	Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8583-8588.	7.1	233
120	Replacing the Combined Test by Cell-Free DNA Testing in Screening for Trisomies 21, 18 and 13: Impact on the Diagnosis of Other Chromosomal Abnormalities. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 174-184.	1.4	51
121	Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 156-173.	1.4	132
122	A new direction for prenatal chromosome microarray testing: software-targeting for detection of clinically significant chromosome imbalance without equivocal findings. <i>PeerJ</i> , 2014, 2, e354.	2.0	15
123	Midbrain and Falx in Fetuses with Absent Corpus Callosum at 11â€“13 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 41-46.	1.4	17
124	Maternal serum visfatin at 11â€“13 weeksâ€™ gestation in preeclampsia. <i>Journal of Human Hypertension</i> , 2013, 27, 261-264.	2.2	16
125	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 8-15.	1.4	464
126	Combined Screening for Preeclampsia and Small for Gestational Age at 11â€“13 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 16-27.	1.4	180

#	ARTICLE	IF	CITATIONS
127	Maternal and Neonatal Outcomes of Successful Kielland's Rotational Forceps Delivery. <i>Obstetrics and Gynecology</i> , 2013, 121, 1032-1039.	2.4	40
128	Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2013, 34, 241-247.	1.4	31
129	Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications. <i>Prenatal Diagnosis</i> , 2013, 33, 839-847.	2.3	54
130	Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study. <i>Journal of Human Hypertension</i> , 2013, 27, 38-43.	2.2	54
131	Maternal serum vitamin D levels at 11-13 weeks of gestation in preeclampsia. <i>Journal of Human Hypertension</i> , 2013, 27, 115-118.	2.2	40
132	Maternal racial origin and adverse pregnancy outcome: a cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 278-285.	1.7	83
133	Procedure-related pregnancy loss following invasive prenatal sampling: time for a new approach to risk assessment and counseling. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 135-142.	0.4	4
134	A Competing Risks Model in Early Screening for Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 171-178.	1.4	182
135	Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia. <i>Journal of Human Hypertension</i> , 2012, 26, 253-258.	2.2	13
136	Maternal serum placental growth hormone at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1796-1799.	1.5	15
137	Metabolomics and first-trimester prediction of early-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1840-1847.	1.5	101
138	First-trimester maternal serum vitamin D and mode of delivery. <i>British Journal of Nutrition</i> , 2012, 108, 1972-1975.	2.3	30
139	Maternal Serum Vitamin D at 11-13 Weeks in Pregnancies Delivering Small for Gestational Age Neonates. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 103-108.	1.4	25
140	Multiplex ligation-dependent probe amplification (MLPA): a reliable alternative for fetal chromosome analysis?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1383-1386.	1.5	7
141	Maternal Hemodynamics at 11-13 Weeks' Gestation in Gestational Diabetes Mellitus. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 216-220.	1.4	20
142	Maternal Hemodynamics at 11-13 Weeks of Gestation in Pregnancies Delivering Small for Gestational Age Neonates. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 231-238.	1.4	25
143	Maternal Serum Placental Growth Factor in Prospective Screening for Aneuploidies at 8-13 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 87-93.	1.4	54
144	OS084. Maternal haemodynamics at 11-13 weeks of gestation and adverse pregnancy outcomes. <i>Pregnancy Hypertension</i> , 2012, 2, 223-224.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Maternal Hemodynamics in Normal Pregnancies at 11â€“13 Weeksâ€™ Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 179-185.	1.4	19
146	Maternal hemodynamics at 11â€“13 weeks' gestation and risk of preâ€eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 28-34.	1.7	76
147	Criteria for Screening and Diagnosis of Gestational Diabetes Mellitus in the First Trimester of Pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 108-115.	1.4	42
148	Prediction of Small-for-Gestation Neonates from Biophysical and Biochemical Markers at 11â€“13 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 148-154.	1.4	153
149	First trimester maternal uterine artery Doppler examination in HIV-positive women. <i>HIV Medicine</i> , 2011, 12, 632-636.	2.2	3
150	Maternal serum 25-hydroxyvitamin D levels at 11+0-13+6â€fweeks in pregnant women with diabetes mellitus and in those with macrosomic neonates. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 951-955.	2.3	30
151	Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. <i>PLoS ONE</i> , 2011, 6, e21791.	2.5	243
152	Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. <i>Prenatal Diagnosis</i> , 2011, 31, 135-141.	2.3	187
153	Prediction of miscarriage and stillbirth at 11â€“13 weeks and the contribution of chorionic villus sampling. <i>Prenatal Diagnosis</i> , 2011, 31, 38-45.	2.3	81
154	Prediction of early, intermediate and late preâ€eclampsia from maternal factors, biophysical and biochemical markers at 11â€“13 weeks. <i>Prenatal Diagnosis</i> , 2011, 31, 66-74.	2.3	377
155	Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11â€“13 weeks. <i>Prenatal Diagnosis</i> , 2011, 31, 75-83.	2.3	101
156	Maternal serum insulinâ€like growth factorâ€binding proteinâ€1 (IGFBPâ€1) at 11â€“13 weeks in preâ€eclampsia. <i>Prenatal Diagnosis</i> , 2011, 31, 196-201.	2.3	12
157	Maternal serum adiponectin at 11 to 13 weeks of gestation in the prediction of macrosomia. <i>Prenatal Diagnosis</i> , 2011, 31, 479-483.	2.3	34
158	Adrenal gland length in euploid and trisomy 18 fetuses at 11â€“13 weeks. <i>Prenatal Diagnosis</i> , 2011, 31, 773-777.	2.3	3
159	Fetal RHD genotype detection from circulating cellâ€free fetal DNA in maternal plasma in nonâ€sensitized RhD negative women. <i>Prenatal Diagnosis</i> , 2011, 31, 802-808.	2.3	57
160	Association of placental volume measured by MRI and birth weight percentile. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 1125-1130.	3.4	38
161	Maternal Serum Adiponectin at 11â€“13 Weeks of Gestation in Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 208-215.	1.4	24
162	Maternal Serum Visfatin at 11â€“13 Weeks of Gestation in Gestational Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, 609-613.	3.2	78

#	ARTICLE	IF	CITATIONS
163	Maternal Serum Adiponectin at 11-13 Weeks of Gestation in Pregnancies Delivering Small for Gestation Neonates. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 274-279.	1.4	5
164	Contribution of Method of Conception on Pregnancy Outcome after the 11-13 Weeks Scan. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 9-22.	1.4	32
165	Maternal Serum Progesterone-Induced Blocking Factor at 11-13 Weeks TM Gestation in Spontaneous Early Preterm Delivery. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 197-200.	1.4	14
166	Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 53-59.	1.4	8
167	Normal Range of Maternal Serum Vitamin D at 11-13 Weeks TM Gestation. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 94-99.	1.4	12
168	Maternal Serum β -Fetoprotein at 11-13 Weeks TM Gestation in Spontaneous Early Preterm Delivery. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 88-93.	1.4	29
169	Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. <i>Hypertension in Pregnancy</i> , 2011, 30, 194-202.	1.1	6
170	Maternal Plasma P-selectin at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. <i>Hypertension in Pregnancy</i> , 2011, 30, 311-321.	1.1	10
171	Maternal Serum Alpha-Fetoprotein in Normal Pregnancy at 11-13 Weeks TM Gestation. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 274-279.	1.4	15
172	Fetal <i>RHD</i> Genotyping in Maternal Plasma at 11-13 Weeks of Gestation. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 301-306.	1.4	53
173	Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation. <i>Human Reproduction</i> , 2011, 26, 1659-1664.	0.9	31
174	Placental Volume at 11-13 Weeks TM Gestation in the Prediction of Birth Weight Percentile. <i>Fetal Diagnosis and Therapy</i> , 2011, 30, 23-28.	1.4	72
175	Maternal Serum Human Placental Growth Hormone (hPGH) at 11 to 13 Weeks of Gestation in Preeclampsia. <i>Hypertension in Pregnancy</i> , 2011, 30, 74-82.	1.1	11
176	Maternal and neonatal outcomes following Kielland's rotational forceps delivery. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2010, 95, Fa9-Fa9.	2.8	3
177	Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. <i>Prenatal Diagnosis</i> , 2010, 30, 191-197.	2.3	48
178	Maternal serum insulin-like growth factor-1 at 11-13 weeks in preeclampsia. <i>Prenatal Diagnosis</i> , 2010, 30, 1026-1031.	2.3	26
179	Fetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. <i>Prenatal Diagnosis</i> , 2010, 30, 918-923.	2.3	38
180	Maternal Serum Placental Protein 13 at Eleven to Thirteen Weeks in Chromosomally Abnormal Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2010, 27, 72-77.	1.4	7

#	ARTICLE	IF	CITATIONS
181	Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21. <i>Clinical Chemistry</i> , 2010, 56, 459-463.	3.2	125
182	Effect of Chorionic Villus Sampling on Uterine Artery Doppler. <i>Fetal Diagnosis and Therapy</i> , 2010, 28, 9-13.	1.4	5
183	Maternal Thyroid Function at 11–13 Weeks of Gestation. <i>Fetal Diagnosis and Therapy</i> , 2010, 27, 156-163.	1.4	38
184	Synergy of Total PLAC4 RNA Concentration and Measurement of the RNA Single-Nucleotide Polymorphism Allelic Ratio for the Noninvasive Prenatal Detection of Trisomy 21. <i>Clinical Chemistry</i> , 2010, 56, 73-81.	3.2	57
185	Chorionic Villus Sampling at 11 to 13 Weeks of Gestation and Hypertensive Disorders in Pregnancy. <i>Obstetrics and Gynecology</i> , 2010, 116, 374-380.	2.4	12
186	Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker. <i>PLoS ONE</i> , 2010, 5, e15244.	2.5	33
187	Systematic Identification of Placental Epigenetic Signatures for the Noninvasive Prenatal Detection of Edwards Syndrome. <i>PLoS ONE</i> , 2010, 5, e15069.	2.5	25
188	Multiplex ligation-dependent probe amplification: a reliable and cost efficient 'single-test' alternative for fetal chromosome analysis?. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2010, 95, Fa17-Fa18.	2.8	0
189	Maternal Serum Activin A at 11–13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2009, 25, 320-327.	1.4	35
190	Maternal plasma inhibin A at 11–13 weeks of gestation in hypertensive disorders of pregnancy. <i>Prenatal Diagnosis</i> , 2009, 29, 753-760.	2.3	61
191	Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. <i>Prenatal Diagnosis</i> , 2009, 29, 847-851.	2.3	9
192	Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. <i>Prenatal Diagnosis</i> , 2009, 29, 934-938.	2.3	38
193	Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia. <i>Prenatal Diagnosis</i> , 2009, 29, 1103-1108.	2.3	97
194	First trimester urinary placental growth factor and development of preeclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2009, 116, 643-647.	2.3	27
195	First-Trimester Prediction of Hypertensive Disorders in Pregnancy. <i>Hypertension</i> , 2009, 53, 812-818.	2.7	389
196	Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of preeclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2008, 32, 732-739.	1.7	222
197	Comparison of closure of subcutaneous tissue versus non-closure in relation to wound disruption after abdominal hysterectomy in obese patients. <i>Journal of Postgraduate Medicine</i> , 2000, 46, 26-8.	0.4	19
198	Rupture of left horn of bicornuate uterus at twenty weeks of gestation. <i>Journal of Postgraduate Medicine</i> , 2000, 46, 39-40.	0.4	11